Sime Armoyan Purchases 17,600 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan acquired 17,600 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Price Performance

Shares of Knight Therapeutics stock opened at C$5.55 on Wednesday. Knight Therapeutics Inc. has a 1-year low of C$5.09 and a 1-year high of C$6.23. The firm’s 50-day moving average price is C$5.53 and its two-hundred day moving average price is C$5.56. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. The stock has a market capitalization of C$561.38 million, a price-to-earnings ratio of -18.53, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a report on Friday, November 15th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.